Current and past trends in life sciences deal-making activity

Posted by Michelle Choi on Fri, May 29, 2020

Cody Powers and Christopher Shapiro co-wrote this blog post with Michelle Choi.

Access COVID-19 resources

In our last blog post, we introduced a framework to assess the impact of COVID-19 on life sciences transaction activity. We noted that, in general, transaction volume declines following recessions and market uncertainty, but there’s evidence to suggest total deal value in these cases has been less affected vs. volume, with significant larger deals observed during prior down periods. In this post, we aim to further analyze these trends and assess how they can help inform the life sciences deal-making landscape today.


>
Read More

Using social media analytics to creatively gather insights

Posted by Anchal Ahuja on Mon, May 18, 2020

Sonal Singh, Pranava Goundan, and Deepak Sharma co-wrote this blog post with Anchal Ahuja.

Access COVID-19 resources

The ongoing global pandemic has been a whirlwind to say the least. Many companies want to understand the implications of COVID-19 as our day-to-day lives are being upended around the globe: How do we keep our people and customers safe? How do we enable tools and technologies to digitally connect our workforce?


>
Read More

COVID-19 vaccines: Who might win the race to the global market?

Posted by Kristyn Feldman on Fri, May 15, 2020

Samaya Krishnan, Parul Rewari, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

In the face of the COVID-19 pandemic, the world is racing to find a safe and effective vaccine for the SARS-CoV2 virus, and industry and academic researchers have initiated clinical trials across the world to test various candidates. In upcoming blogs, we will explore the different vaccine technologies in clinical development, along with where they originated and where they might be tested and manufactured.


>
Read More

Addressing COVID-19 challenges: Quick wins for medical affairs leaders

Posted by Sunil John on Fri, May 08, 2020

Access COVID-19 resources

The current COVID-19 crisis has rapidly changed the face of the world and the pharmaceutical industry landscape. Virtual trials, large-scale use of telemedicine and non-personal engagements are a few such changes that the pharmaceuticals world is experiencing, and pharma companies need to adapt swiftly.


>
Read More

Will COVID-19 affect the relationship between mega-payers and pharma companies?

Posted by Suman Sen on Thu, May 07, 2020

Nitin Jain and Matt Ruple co-authored this post with Suman Sen.

Access COVID-19 resources

The past few years have brought tremendous change to the healthcare landscape, largely driven by a pursuit to increase scale, contain costs and exert decision-making control. The trends highlighted in this blog post, along with ideas for how pharma companies need to respond, were already strong before the COVID-19 outbreak. The changes to the life sciences landscape will continue to accelerate as the pandemic creates additional pressures.


>
Read More